# Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer

> **NCT00047801** · PHASE1,PHASE2 · COMPLETED · sponsor: **Telik** · enrollment: 28 (—)

## Conditions studied

- Carcinoma, Non-small-cell Lung

## Interventions

- **DRUG:** TLK286 in combination with docetaxel

## Key facts

- **NCT ID:** NCT00047801
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 28 (—)
- **Last updated:** 2011-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047801, "Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00047801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*